Soligenix (NASDAQ: SNGX) establishes $3.45M at-the-market stock sale

Rhea-AI Filing Summary

Soligenix, Inc. has entered into an at-the-market equity sales agreement with Rodman & Renshaw, LLC, allowing the company to sell shares of its common stock from time to time with an aggregate offering price of up to $3,450,000. Sales, if any, will be made through Rodman as sales agent on The Nasdaq Capital Market or other U.S. trading markets, at market-related or negotiated prices, as defined in Rule 415 under the Securities Act.

The company will control key parameters for each sales period, such as the number of shares sold, time window, daily volume limits, and any minimum price. Soligenix is not obligated to sell any shares, may suspend solicitations, and either party may terminate the agreement under specified conditions, with the program ending no later than December 15, 2026 unless ended earlier. Rodman will receive a commission of up to 3.0% of gross proceeds, and shares will be issued under Soligenix’s effective Form S-3 shelf registration statement and a related prospectus supplement.

false 0000812796 0000812796 2026-01-23 2026-01-23 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

The Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported):  January 23, 2026

Commission File No. 000-16929

Soligenix, Inc.

(Exact name of small business issuer as specified in its charter)

delaware		41-1505029
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification Number)

29 Emmons Drive, Suite B-10 Princeton, NJ		08540
(Address of principal executive offices)		(Zip Code)

(609) 538-8200

(Issuer’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

¨   Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨   Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨   Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $.001 per share		SNGX		The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 8.01. Other Events.

On January 23, 2026, Soligenix, Inc. (the “Company”) and Rodman & Renshaw, LLC (“Rodman”) entered into an At Market Issuance Sales Agreement (as amended, the “Sales Agreement”), pursuant to which the Company may sell from time to time, at its option, shares of its common stock, par value $0.001 per share, having an aggregate offering price of up to $3,450,000, through Rodman, as sales agent.

Under the Sales Agreement, the Company will set the parameters for the sale of shares, including the number of shares to be issued, the time period during which sales are requested to be made, limitation on the number of shares that may be sold in any one trading day and any minimum price below which sales may not be made. Subject to the terms and conditions of the Sales Agreement, Rodman may sell the shares by any method permitted by law deemed to be an “at-the-market offering” as defined in Rule 415 promulgated under the Securities Act of 1933, as amended (the “Securities Act”), including sales made directly on The Nasdaq Capital Market, the trading market for our common stock, or any other existing trading market in the United States for the common stock, sales made to or through a market maker other than on an exchange, at prices related to the prevailing market prices or at negotiated prices. The Company cannot provide any assurances that it will issue any shares pursuant to the Sales Agreement. The Sales Agreement may be terminated by the Company upon notice to Rodman or by Rodman upon notice to the Company, or at any time under certain circumstances, including but not limited to the occurrence of a material adverse change in the Company. The offering of shares of common stock pursuant to the Sales Agreement will terminate upon the earliest of (a) December 15, 2026, (b) the sale of all of the shares of common stock subject to the Sales Agreement, (c) the termination of the Sales Agreement by Rodman or the Company, as permitted therein, and (d) the mutual agreement of the parties.

The Company will pay Rodman a fixed commission rate equal to up to 3.0% of the gross proceeds from the sale of shares sold under the Sales Agreement. The Company has no obligation to sell any shares under the Sales Agreement, and may suspend solicitation and offers under the Sales Agreement. The shares will be issued pursuant to the Company’s shelf registration statement on Form S-3, as amended (File No. 333-274265), originally filed with the U.S. Securities and Exchange Commission (the “SEC”) on August 30, 2023, and that was declared effective on December 15, 2023, the base prospectus filed as part of such registration statement, and the prospectus supplement dated January 23, 2026, filed by the Company with the SEC.

The Company has agreed in the Sales Agreement to provide indemnification and contribution to Rodman against certain liabilities, including liabilities under the Securities Act.

This Current Report on Form 8-K shall not constitute an offer to sell or the solicitation of an offer to buy any security nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state.

The description of the Sales Agreement presented here does not purport to be complete and is qualified in its entirety by reference to the Sales Agreement which is filed as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated herein by reference. The opinion of the Company’s counsel regarding the validity of the shares that will be issued pursuant to the Sales Agreement under the prospectus supplement filed on August 16, 2024, is filed herewith as Exhibit 5.1.

2

Item 9.01. Financial Statements and Exhibits.

(d)           Exhibits.

Exhibit No.		Description
5.1		Opinion of Duane Morris LLP
10.1		At Market Issuance Sales Agreement dated January 23, 2026 between Soligenix, Inc. and Rodman & Renshaw LLC
23.1		Consent of Duane Morris LLP (included in Exhibit 5.1)
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

3

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Soligenix, Inc.
January 23, 2026	By:	/s/ Christopher J. Schaber
		Christopher J. Schaber, Ph.D.
		President and Chief Executive Officer
		(Principal Executive Officer)

4

FAQ

What did Soligenix (SNGX) announce in this 8-K filing?

Soligenix, Inc. disclosed that it entered into an At Market Issuance Sales Agreement with Rodman & Renshaw, LLC. Under this arrangement, the company may sell shares of its common stock from time to time through Rodman as sales agent, up to an aggregate offering price of $3,450,000, under its existing shelf registration on Form S-3.

What is the size of Soligenix’s at-the-market offering program with Rodman?

The at-the-market program permits Soligenix to sell, at its option, shares of common stock having an aggregate offering price of up to $3,450,000 through Rodman & Renshaw, LLC as sales agent.

How will Rodman & Renshaw be compensated under the Soligenix sales agreement?

Under the Sales Agreement, Soligenix will pay Rodman & Renshaw a fixed commission of up to 3.0% of the gross proceeds from any shares of common stock sold through the at-the-market program.

How long will Soligenix’s at-the-market offering remain in place?

The offering of common stock under the Sales Agreement will terminate on the earliest of December 15, 2026, the sale of all shares subject to the agreement, termination by either Soligenix or Rodman as permitted, or mutual agreement of the parties.

Is Soligenix required to sell shares under this at-the-market program?

No. The filing states that Soligenix has no obligation to sell any shares under the Sales Agreement and may suspend solicitations and offers at its discretion, even though it may sell up to $3,450,000 of common stock if it chooses.

Under what registration statement will Soligenix sell shares in this program?

The shares to be sold under the Sales Agreement will be issued pursuant to Soligenix’s shelf registration statement on Form S-3 (File No. 333-274265), which was declared effective on December 15, 2023, together with the base prospectus and a prospectus supplement dated January 23, 2026.

What legal opinions and exhibits are included with Soligenix’s 8-K about the sales agreement?

The filing includes an opinion of Duane Morris LLP regarding the validity of the shares as Exhibit 5.1, the At Market Issuance Sales Agreement with Rodman & Renshaw as Exhibit 10.1, the related consent of Duane Morris LLP as Exhibit 23.1, and the cover page interactive data file as Exhibit 104.